The differing changes in expression of BCRP and NOTCH3 emphasize the importance of tumor profiling and precision oncology in therapeutic strategies for PDAC, and the need to target nodal proteins like APE1 that can affect multiple pathways. This evidence concerns the gene NOTCH3 and neoplasm.